CD8A and neoplasm: The concomitant administration of an anti-PD-1/PD-L1 antibody was able to overcome this adaptive resistance and led to the generation of effective and durable CD8+ T cell-mediated immune response, resulting in local and distal tumor control, providing long-term survival and protection against tumor re-challenge.